Atopic Dermatitis
Conditions
Interventions
Drug: LY3454738
Administered SC
Drug: Placebo
Administered SC
[Study Arms]
Experimental: LY3454738 Dose 1
Participants will receive LY3454738 subcutaneously (SC).
Intervention: Drug: LY3454738
Experi
Sponsors
Masaki Takeshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Are candidates for systemic therapy. ISA specific: Have moderate-to-severe AD, defined as meeting all of the following criteria, at the first dosing visit: EASI score greater than or equal to (>=)16 vIGA-AD score >=3, and >=10% of BSA involvement (per EASI BSA). Have applied at least 1 emollient every day for at least 2 weeks before the day of the first dose of study intervention in this ISA and agree to daily use of at least 1 emollient continuously throughout the study.
Exclusion criteria
Exclusion criteria: ISA specific: Have, in the screening period, any of the skin conditions, infections, or medical conditions listed under master IMMB. Are currently being treated with topical or systemic therapy Recent treatment with experimental (biologics and/or small molecules) - doesn't apply for subset of participants who must have been exposed to biologics and/or small molecules.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of Participants Achieving Eczema Area and Severity Index (EASI) 75 [ Time Frame: Week 16 ] | — |
Countries
Canada, China, Hungary, Italy, Japan, Korea, Poland, Republic of Mexico, Taiwan, United States
Contacts
Public ContactTrial Guide Call Center
Eli Lilly Japan K.K.
Outcome results
None listed